Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva 'Pay-For-Delay Case Will Keep Courts Busy For Years'

Executive Summary

Once again the European Commission has the marketing practices of the pharmaceutical industry in its sights, with Teva the latest company in the spotlight for an alleged 'pay-for-delay' agreement over the sleep disorder drug modafinil.

You may also be interested in...

EU Pay-For-Delay Ruling Against Lundbeck Sends Signal To Others, Including UK Competition Body

The EU’s General Court has upheld the European Commission’s decision to fine Lundbeck and a number of generics firms for agreeing to keep generic versions of the antidepressant citalopram off the market in return for payments. The ruling could have implications for other similar cases such as that involving GlaxoSmithKline’s paroxetine in the UK.

Servier and generics firms to appeal EU verdict on perindopril 'sweetheart' deals

The European Commission has imposed fines totaling Euros 427.7 million on Servier and five producers of generic medicines for anti-competitive practices – a decision that the French drug maker says sets a "regrettable precedent" for industries that rely on intellectual property1,2.

AstraZeneca Inks Pact With EU For Coronavirus Vaccine

The agreement will give all EU member states the option to access the drug major's investigational COVID-19 vaccine dubbed AZD1222 "in an equitable manner at no profit during the pandemic."


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts